Entrusted financial announcement
Release time:
2021-05-20
证券简称:尖峰集团 证券代码:600668 编号:临2020-012
浙江尖峰集团股份有限公司
委托理财公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
- 委托理财受托方:华夏银行股份有限公司金华分行
- 委托理财金额:10,000万元人民币
- 委托理财产品名称:慧盈人民币单位结构性存款产品20231753
- 委托理财投资类型:保本浮动收益型结构性存款
- 委托理财期限:2020年5月12日—2020年8月12日
- 履行的审议程序:2019年4月26日,公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》。授权公司董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2019年4月30日在上海证券交易所网站等披露的《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
一、本次委托理财概况
(一)委托理财目的
公司在不影响主营业务的正常开展、日常运营资金周转需要和资金安全的前提下,使用暂时闲置自有资金10,000万元购买华夏银行金华分行发售的慧盈人民币单位结构性存款产品。本产品为保本浮动收益型存款产品,安全性高、流动性好、风险性低。公司通过进行适度的低风险理财产品投资业务,有利于提高资金使用效率,且获得一定的理财收益。
(二)资金来源
本次委托理财的资金来源系公司自有资金。
(三)委托理财产品的基本情况
|
受托方 名称 |
产品 类型 |
产品 名称 |
金额 (万元) |
预计年化 收益率 |
预计收益金额 (万元) |
|
华夏银行股份有限公司金华分行 |
银行结构性存款产品 |
慧盈人民币单位结构性存款产品 |
10,000 |
1.54%—3.80% |
38.82-95.78 |
|
产品 期限 |
收益 类型 |
结构化 安排 |
参考年化 收益率 |
预计收益 (万元) |
是否构成 关联交易 |
|
92天 |
保本浮动收益型 |
无 |
1.54%—3.80% |
38.82-95.78 |
否 |
(四)公司对委托理财相关风险的内部控制
1、委托理财情况由公司审计部门进行日常监督,定期对公司委托理财的进展情况、盈亏情况、风险控制情况和资金使用情况进行审计、核实。
2、公司进行委托理财,应当选择资信、财务状况良好、盈利能力强的合格专业理财机构作为受托方,并与受托方签订书面合同,明确委托理财的金额、期间、投资品种、双方的权利义务及法律责任等,必要时要求提供担保。公司董事会指派公司财务负责人跟踪委托理财的进展情况及投资安全状况。财务负责人发现公司委托理财出现异常情况时应当及时向董事会报告,以便董事会立即采取有效措施回收资金,避免或减少公司损失。
3、公司独立董事可以对委托理财情况进行检查。独立董事在公司内部审计核查的基础上,以董事会审计委员会核查为主,必要时由二名以上独立董事提议,有权聘任独立的外部审计机构进行委托理财的专项审计。独立董事应对提交董事会审议的委托理财事项发表独立意见。
4、公司监事会有权对公司委托理财情况进行定期或不定期的检查。如发现违规操作情况可提议召开董事会审议停止公司的相关投资活动。
5、公司委托理财具体执行人员及其他知情人员在相关信息公开披露前不得将公司投资情况透露给其他个人或组织,但法律、法规或规范性文件另有规定的除外。
6、凡违反相关法律法规、本制度及公司其他规定或由于工作不尽职,致使公司遭受损失或收益低于预期,将视具体情况,追究相关人员的责任。
本次公司购买华夏银行发行的保本浮动收益型结构性存款,在前述董事会对董事长的授权范围内,该产品风险程度低,符合公司内部资金管理要求。
二、本次委托理财的具体情况
(一)委托理财合同主要条款
客户:浙江尖峰集团股份有限公司
银行:华夏银行股份有限公司金华分行
|
产品名称 |
慧盈人民币单位结构性存款产品20231753 |
|
产品代码 |
HY20231753 |
|
挂钩标的 |
上海期货交易所黄金期货价格AU2012 (以下简称“黄金期货价格”) |
|
产品期限 |
92天 |
|
产品类型 |
保本浮动收益型存款产品 |
|
本金保证 |
银行在本产品到期时保证存款本金 |
|
存款成立日 |
2020年5月12日 |
|
存款到期日 |
2020年8月12日 |
|
本金及收益支付 |
2020年8月12日,产品正常到期;如产品因故提前终止的,则到期日以华夏银行通知为准。 产品到期日当日不计算收益,华夏银行于到期日当日的22:30至24:00一次性支付本金及收益。 |
|
预期年化收益率 |
根据产品挂钩标的表现,预期年化收益率在1.54%至3.80%之间(详见“产品收益分析与计算”): 1、若观察期挂钩标的收盘价格均小于障碍价格,且结算价格大于或等于执行价格1,则预期年化收益率 =3.80% 2、若观察期挂钩标的收盘价格均小于障碍价格,且结算价格小于执行价格1,则预期年化收益率 =3.70% 3、若观察期任一交易日挂钩标的收盘价格大于或等于障碍价格,且结算价格大于或等于执行价格2,则预期年化收益率 =3.70% 4、若观察期任一交易日挂钩标的收盘价格大于或等于障碍价格,且结算价格小于执行价格2,则预期年化收益率=1.54% |
|
提前终止权 |
一、客户提前终止权 1、除非出现如下任一情形,否则客户无权提前终止本产品: (1)华夏银行根据法律法规、监管规定或市场重大变动对本产品的投资范围、投资品种或投资比例进行调整,客户不接受上述调整的; (2)华夏银行根据法律法规、监管规定或国家政策规定,对本产品的收费项目、条件、标准和方式进行调整,客户不接受上述调整的; 2、华夏银行对本产品做调整的,将通过销售人员通知客户。客户不接受调整的,应在通知确定的期限内向华夏银行申请提前终止并办理相关手续;若投资者在期限届满继续持有本产品,则视为接受对本产品的调整。 二、华夏银行提前终止权 1、出现下列情形,华夏银行有权提前终止本产品: (1)遇国家法律法规或金融政策出现重大调整并影响本产品正常运作; (2)根据市场及投资运作情况经华夏银行合理判断认为需要提前终止本产品。 2、华夏银行提前终止本产品的,在提前终止日前3个工作日通过销售人员告知客户。 由于华夏银行在特定情况下提前终止本产品,本产品的实际期限可能小于预定期限。如果本产品提前终止,则投资者将无法实现期初预期的全部收益。 |
|
预期收益计算方法 |
预期收益=存款本金×预期年化收益率×产品期限÷365 |
|
税款 |
产品收益的应纳税款由投资者自行申报及缴纳,但若根据法律法规等规定或税务等国家机关的命令或要求,华夏银行有义务代扣代缴投资者承担的税费时,华夏银行将进行代扣代缴。 |
|
其他规定 |
1、认购申请日(含)至认购撤销日(不含),客户资金按华夏银行每日挂牌活期存款利率计算利息。 2、认购申请日(含)至成立日(不含),客户资金按华夏银行每日挂牌活期存款利率计算利息,且该利息不计入认购本金。 |
(二)委托理财的资金投向
本次公司委托理财的资金投向为华夏银行结构性存款产品。
(三)风险控制分析
公司本次使用自有资金购买华夏银行金华分行发售的保本浮动收益型结构性存款,在公司第十届董事会第10次会议授权董事长决策范围之内。公司财务部建立台账负责对短期理财产品进行管理,建立健全会计账目,做好资金使用的财务核算工作。公司在本次交易后将履行信息披露义务,并实时跟踪进展情况及时披露。
华夏银行结构性存款属于保本浮动收益型产品,华夏银行股份有限公司金华分行承诺保障结构性存款本金,因此该产品风险程度较低,符合公司《委托理财管理制度》的要求。
三、委托理财受托方的情况
(一)受托方的基本情况
|
名称 |
成立时间 |
法定代表人 |
注册 资本 (万元) |
主营业务 |
主要股东及实际控制人 |
是否为本次交易专设 |
|
华夏银行股份有限公司 |
1992-10-14 |
李民吉 |
1538722.3983 |
吸收公众存款;发放短期、中期和长期贷款;办理国内外结算;办理票据承兑与贴现;发行金融债券;代理发行、代理兑付、承销政府债券;买卖政府债券、金融债券;从事同业拆借;买卖、代理买卖外汇;从事银行卡业务;提供信用证服务及担保;代理收付款项;提供保管箱服务;结汇、售汇业务;保险兼业代理业务;经中国银行业监督管理委员会批准的其他业务。(企业依法自主选择经营项目,开展经营活动;依法须经批准的项目,经相关部门批准后依批准的内容开展经营活动;不得从事本市产业政策禁止和限制类项目的经营活动。) |
首钢集团有限公司、国网英大国际控股集团有限公司、中国人民财产保险股份有限公司等 |
否 |
(二)受托方最近一年又一期主要财务指标
单位:百万元
|
|
2019年12月31日 |
2020年3月31日 |
|
总资产 |
3,020,789 |
3,108,998 |
|
归属于股东的净资产 |
267,588 |
272,846 |
|
|
2019年度 |
2020年1-3月 |
|
营业收入 |
84,734 |
23,594 |
|
归属于股东的净利润 |
21,905 |
4,840 |
(三)华夏银行股份有限公司与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
四、对公司的影响
(一)本公司最近一年又一期主要财务指标
单位:万元
|
项目 |
2019年12月31日 |
2020年3月31日 |
|
总资产 |
547,517.79 |
561,077.58 |
|
总负债 |
139,487.88 |
143,631.62 |
|
归属于公司股东的净资产 |
378,910.99 |
391,427.86 |
|
|
2019年度 |
2020年1-3月 |
|
经营性现金流量净额 |
51,998.13 |
-2,709.08 |
|
营业收入 |
354,753.76 |
53,758.84 |
|
归属于公司股东的净利润 |
72,468.81 |
12,265.65 |
公司本次购买华夏银行结构性存款理财产品是在不影响主营业务的正常开展、日常运营资金周转需要和资金安全的前提下,使用短期闲置自有资金进行委托理财业务,有利于提高公司资金使用效率。
(二)截止2020年3月31日,公司货币资金为45,084.20万元,本次购买华夏银行结构性存款支付的金额占最近一期期末货币资金的22.18%,对本公司未来主营业务、财务状况、经营成果和现金流量等不会造成重大的影响。
(三)根据企业会计准则第22号—《金融工具确认和计量》规定,该结构性银行存款符合以摊余成本计量的金融资产,列示于资产负债表—其他流动资产,利息收益计入利润表—投资收益。
五、风险提示
尽管本公司购买的结构性存款属于短期保本浮动收益型的低风险理财产品,但金融市场受宏观经济影响较大,不排除该项投资受到市场风险、信用风险、政策风险、流动性风险、不可抗力风险等风险从而影响收益。
六、独立董事意见
公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长决定委托理财的议案》,独立董事发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
七、截至本公告日,公司最近十二个月使用自有资金或募集资金委托理财的情况 单位:万元
|
序号 |
理财产品类型 |
实际投入 金额 |
实际收回 本金 |
实际收益 |
尚未收回 本金金额 |
|
1 |
汇利丰2019年5015期对公定制人民币结构性存款产品 |
10,000.00 |
10,000.00 |
104.71 |
/ |
|
2 |
薪加薪16号人民币结构性存款产品 |
8,000.00 |
8,000.00 |
136.32 |
/ |
|
3 |
薪加薪16号人民币结构性存款产品 |
8,000.00 |
8,000.00 |
115.51 |
/ |
|
4 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
48.70 |
/ |
|
5 |
慧盈人民币单位结构性存款产品 |
5,000.00 |
5,000.00 |
50.03 |
/ |
|
6 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
4,000.00 |
27.34 |
/ |
|
7 |
渤海银行S190019号结构性存款理财产品 |
10,000.00 |
10,000.00 |
99.73 |
/ |
|
8 |
薪加薪16号人民币结构性存款产品 |
10,000.00 |
10,000.00 |
33.75 |
/ |
|
9 |
渤海银行S191620号结构性存款理财产品 |
5,000.00 |
5,000.00 |
50.49 |
/ |
|
10 |
渤海银行S192012号结构性存款理财产品 |
3,000.00 |
3,000.00 |
29.92 |
/ |
|
11 |
慧盈人民币单位结构性存款产品 |
3,000.00 |
3,000.00 |
29.96 |
/ |
|
12 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
/ |
/ |
5,000.00 |
|
13 |
结构性存款 |
5,000.00 |
5,000.00 |
18.74 |
/ |
|
14 |
慧盈人民币单位结构性存款产品 |
5,000.00 |
/ |
/ |
5,000.00 |
|
15 |
薪加薪16号人民币结构性存款产品 |
10,000.00 |
/ |
/ |
10,000.00 |
|
16 |
慧盈人民币单位结构性存款产品 |
10,000.00 |
/ |
/ |
10,000.00 |
|
合计 |
106,000.00 |
76,000.00 |
745.20 |
30,000.00 |
|
|
最近12个月内单日最高投入金额 |
50,000.00 |
||||
|
最近12个月内单日最高投入金额/最近一年净资产(%) |
13.20 |
||||
|
最近12个月委托理财累计收益/最近一年净利润(%) |
1.03 |
||||
|
目前已使用的理财额度 |
30,000.00 |
||||
|
尚未使用的理财额度 |
20,000.00 |
||||
|
总理财额度 |
50,000.00 |
||||
特此公告
浙江尖峰集团股份有限公司
董事会
二〇二〇年五月十三日
More information
In the eastern corner of the production area of Jianfeng Health Technology Company, there is a very inconspicuous building. From below, only a few pipes of uneven thickness can be seen on the top and the slogan "Focus on Environmental Protection and Promote Sustainable Development" with red letters on the yellow background on the stainless steel guardrail. Walking up, you can only see several closed pools and a small room with stacks of documents, test tubes, glass bottles and other testing tools on the table. This is the peak and healthy sewage treatment station. The production sewage of the whole factory area is concentrated here. After adjustment (PH adjustment), pre-acidification, anaerobic, anoxic, aerobic (aeration), precipitation and other links, it is discharged into the pipe network after reaching the special discharge standard. Yin Zhiwu, executive deputy general manager of Jianfeng Health, said that because the sewage treatment station in Wucheng District has not yet been built, Jianfeng Health has not yet been able to achieve pipe discharge, and the relevant national laws have strict requirements on the discharge of water pollutants from the extraction pharmaceutical industry. Sewage discharge must reach a special discharge limit, that is, chemical oxygen demand (COD) must be less than 50 mg/L. Enterprise development and environmental protection are both the concept of peak health since its establishment. In March this year, on the basis of the original environmental protection facilities, Jianfeng Health carried out technical renovation of waste gas collection and treatment facilities, and at the same time installed a sealing cover on the sewage treatment station to realize the closed collection of waste gas. Since the trial operation of this facility in mid-May, the overall effect has been obvious. The original treatment tank would emit an unpleasant smell during work, but now the smell has been significantly reduced. Compared with the young enterprise of peak health, the relatively "older" peak pharmaceutical has more experience in sewage treatment and environmental protection. Akihama
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-30
Jianfeng Pharmaceutical Won Advanced Collective of Municipal Red Cross Humanitarian Promotion Award
On April 24, the Red Cross Society of Jinhua issued a circular commending the advanced units and individuals of the 2016 Red Cross Humanitarian Promotion Award. Peak Pharmaceutical Company won the Red Cross Humanitarian Promotion Award for Advanced Collective. The Red Cross is a social relief organization engaged in humanitarian work, with the purpose of carrying forward the spirit of humanity, fraternity and dedication, protecting human life and health, and promoting the cause of peace and progress of mankind. As a socially responsible enterprise, Jianfeng Pharmaceutical has always attached importance to public welfare and charity work, vigorously promoted the spirit of the Red Cross, and vigorously supported the work of the Red Cross with practical actions. In September 2016, at the theme publicity activity of "World First Aid Day" and the opening ceremony of the municipal Red Cross emergency rescue station (point), Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, donated 6 AEDs known as "life-saving artifact" to the Red Cross on behalf of Jianfeng Pharmaceutical, it is equipped with six Red Cross emergency rescue service stations (points), namely, Jinhua high-speed railway station, sports center, cultural center, Shuanglong scenic spot, Siping village scenic spot and Suoyuan village scenic spot. The configuration of AED equipment has played a very good role in improving the emergency rescue capacity of Jinhua's key locations, and has been affirmed by the Red Cross and related units. (Spike Pharmaceuticals)
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31